Pharmacies: Government Funding

Debate between Gregory Stafford and Shockat Adam

Wednesday 9th September 2026 Westminster Hall

[Gregory Stafford (Farnham and Bordon) (Con)]

It is a privilege to serve under your chairmanship, Mr Betts. I welcome the Minister for Public Health and Patient Safety, the right hon. Member for Kingston upon Hull North and Cottingham (Dame Diana Johnson), to her new role and congratulate her on her appointment.

I also congratulate my hon. Friend the Member for Leicester East (Shivani Raja) on securing this most important debate. She spoke very powerfully about the pressures facing community pharmacies and I want to build on her speech by discussing what is happening both in my constituency and nationally.

In Farnham and Bordon, we have access to 15 community pharmacies, which collectively dispense around 142,000 prescriptions every month and deliver around 6,500 flu vaccinations. The Government’s 10-year plan wants more healthcare to be delivered in the community, which is an aim that I think we all support. At the same time, however, the Government appear to be making it harder for those very pharmacies to deliver such care and to remain sustainable.

The reality is that community pharmacies are being asked to do more while facing rising costs. We have seen higher national insurance contributions, increases in the national minimum wage, rising business rates and persistent inflationary pressures. At the same time, pharmacies are dealing with medicine shortages, higher procurement costs and disruption to international supply chains. The financial picture is impossible to ignore. Funding for community pharmacies in 2025-26 was actually £800 million less in real terms than it was in 2015-16. In the last year alone, the number of NHS-prescribed items dispensed by pharmacies and the service volumes increased by 2.3% and 17% respectively.

As the hon. Member for North Somerset (Sadik Al-Hassan) has already highlighted—he was echoed by a number of Members around the Chamber today—the Government’s own independent economic analysis in March 2025 identified a funding gap for pharmacies of £2 billion a year, and trade bodies that have spoken to me identify a structural funding problem. Of course, we on this side of the House welcome additional funding, but pharmacy is not made sustainable by giving with one hand and taking with the other. We need to ensure the long-term viability of community pharmacy and I am very sceptical that the Government’s approach will achieve that.

I turn now to Pharmacy First, which is an excellent example of what can be achieved when we make better use of the skills and expertise available within our NHS. My right hon. Friend the Member for Richmond and Northallerton (Rishi Sunak) is absolutely right to be proud of his Government’s record on this matter. Created and implemented by the last Government, Pharmacy First shows what NHS reform should look like—the right professional, with the right responsibility, delivering the right care in the right place. It should be a game changer and I pay tribute to my right hon. Friend for its introduction.

Pharmacy First recognises that patients with seven common conditions can be safely assessed and treated by qualified pharmacists without there always being a requirement for a GP appointment. However, the scheme is currently limited and not as expansive as it is in Scotland, where it covers up to 30 common conditions. I would like the Government to move rapidly to expand Pharmacy First elsewhere. We should be ambitious about the skills and clinical expertise of our pharmacists.

[Shockat Adam]

Does the hon. Member agree that another opportunity for Pharmacy First—indeed, a generational opportunity—is independent prescribing? That would really unlock the potential of pharmacies and help patients, but it requires both a vision and adequate funding.

[Gregory Stafford]

I entirely agree with the hon. Gentleman. I think that we can use pharmacists and pharmacies much more creatively and in a manner that would in no way put patient safety at risk. In fact, it would allow patients more choice, and free up GPs and other health professionals to do other parts of their job, so he is right.

Community Pharmacy England’s 2026 pharmacy pressures survey makes the scale of the challenge facing pharmacies clear. Drawing on responses from nearly 4,000 pharmacy owners and staff members, it found that 75% of pharmacies are currently losing money, while only 14% reported being profitable. There is little value in providing additional funding for services without recognising the wider cost and workforce pressures facing the sector: 30% of pharmacies have reduced their opening hours and 76% report an impact on patient care, including longer waits and delays in accessing medicine.

That brings me—briefly—to the issue of business rates and the wider cumulative costs facing pharmacies. A pharmacy might occupy a storefront on a high street, but it is not simply another retailer; it is part of the national health service and is an essential provision in our community. As the hon. Member for Strangford (Jim Shannon) outlined, pharmacies are also part of our national resilience. The Government want pharmacies to take on more responsibility, but they face rising costs that have been caused by the Government.

Pharmacies need to be properly considered within the system and not treated simply as another high street retailer. The same issue applies when we consider national insurance increases, and indeed the national living wage. These cumulative increases are having a real impact. Unlike a high street retailer, a pharmacy has contractual obligations to the NHS and a moral responsibility to its patients, so it cannot just increase prices or stop providing a service like other businesses could. As my hon. Friend the Member for South West Hertfordshire (Mr Mohindra) rightly put it, the Government have to recognise the cumulative impact of these terrible decisions when considering future policy.

Parkinson’s Disease

Debate between Gregory Stafford and Shockat Adam

Monday 17th November 2025 Westminster Hall

[Gregory Stafford]

I have also been approached by BeechBand. I hope the Minister agrees that the Medicines and Healthcare products Regulatory Agency and the Government must ensure that where there are new, innovative technologies that could help sufferers of Parkinson’s or any other disease condition, they can get to the frontline to help people as quickly as possible.

[Shockat Adam (Leicester South) (Ind)]

Does the hon. Member agree that early detection is key to fighting this disease? Is he, like me, encouraged by research from Moorfields eye hospital and University College London that found that a scan of the retina—the back of the eye—can detect Parkinson’s disease seven years before any symptoms present?

[Gregory Stafford]

I bow to the hon. Member’s experience on that. I hope the Minister is listening carefully, because these types of innovative technologies can make a significant difference and should be rolled out as quickly as possible.

Living with Parkinson’s brings real financial strain. On average, people spend more than £7,500 each year managing their conditions. That rises to £22,000 when lost earnings are included, so support is not just a clinical need, but an economic one.

In my Farnham and Bordon constituency, which includes Haslemere, Liphook and the surrounding villages, 289 people are currently living with Parkinson’s. The fact that we are—I believe—the only constituency served by three integrated care boards of different sizes brings with it not only challenges but a chance for comparison. Despite their different sizes, some of their challenges are the same, including the increasing number of emergency admissions across all three ICBs. Those numbers lay bare the scale of need and the pressure on services, and underline the urgent requirement for earlier access to specialist care. I raised these concerns in May as the shadow Minister, but I sadly remain unconvinced that the current Government have identified Parkinson’s as a strategic priority.

The new 10-year health plan imagines neighbourhood teams of doctors, nurses, pharmacists, physiotherapists and social workers. It is a positive vision, but it will work only if Parkinson’s specialists are part of those teams. In the Health and Social Care Committee, we often hear about artificial intelligence, remote monitoring and wearable devices, all of which have the potential to transform care through early intervention and better monitoring. The Government must look at those things as well.

I will end with three clear questions. First, in May, the Minister committed to discussing support from the point of diagnosis with Parkinson’s Connect, the Parkinson’s UK programme designed to equip NHS professionals. Have those discussions taken place, and what actions will follow? Secondly, the Minister has said that Parkinson’s nurses are

“worth their weight in gold”—[Official Report, 1 May 2025; Vol. 766, c. 493WH.]

and I agree. What practical measures have been introduced to strengthen training and development for those nurses, particularly those who support patients with the most complex needs?

Thirdly, will the Minister commit to working closely with charities such as Parkinson’s UK to ensure that the 10-year plan gives patients, carers and frontline staff the support they urgently need? Members on both sides of this Chamber share one goal: to get better diagnosis, better treatment and better support for people living with Parkinson’s. Action is what brings progress, and action is what our constituents need and deserve.